A pro-abortion protester attends a demonstrations after a leaked Supreme Court opinion indicated the court may overturn abortion rights.

Medications used to treat miscarriages and ectopic pregnancies could soon be harder to access, experts told Insider. 
The same drugs are used for women who have just had an abortion and could be targeted by new bans.
Already in Texas, some pharmacies are refusing to fill prescriptions for these medications. 

It could soon become difficult to access medications used for miscarriage management and to treat ectopic pregnancies because they are the same drugs used for abortion care.

Insider spoke to legal experts and reproductive health doctors in the wake of the leaked Supreme Court draft opinion, which indicated the justices are poised to overturn the landmark 1973 decision in Roe v. Wade that enshrines a woman’s federal right to an abortion. 

If Roe is, in fact, overturned, access to medications such as methotrexate and misoprostol could be harder to access, experts told Insider.

“The procedure that some people who miscarry get is the same procedure as abortion, same with the medications they take after,” said Heather Shumaker, Director of State Abortion Access at the National Women’s Law Center.

“Some people who have miscarriage management might have a similar regimen to the medication abortion regimen,” she continued.

Dr. Natalie Crawford, a fertility doctor and obstetrician-gynecologist in Austin, said new laws are already having a chilling effect on access to the medication. 

Texas recently passed an abortion ban that outlaws the procedure after a fetal heartbeat is detected, typically about six weeks into pregnancy.

“We are finding some pharmacists refusing to fill prescriptions for these medications, citing SB8 as the reason why,” Crawford told Insider. 

She explained that ectopic pregnancies and incomplete miscarriages are non-viable pregnancies that can “result in maternal death and often be treated with medications that are also abortifacient” …read more

Source:: Business Insider


(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *